# Therapeutic Plasma Exchange, Rituximab and IV Ig for Severe Acute Exacerbation of IPF Admitted in ICU

> **NCT03584802** · NA · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 40 (estimated)

## Conditions studied

- Exacerbation of Idiopathic Pulmonary Fibrosis

## Interventions

- **OTHER:** Therapeutic plasma exchanges
- **OTHER:** Conventional treatment of AE-IPF

## Key facts

- **NCT ID:** NCT03584802
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-16
- **Primary completion:** 2020-10-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03584802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03584802, "Therapeutic Plasma Exchange, Rituximab and IV Ig for Severe Acute Exacerbation of IPF Admitted in ICU". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03584802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*